» Articles » PMID: 17323714

Treatment Options for Atopic Dermatitis

Overview
Specialty Public Health
Date 2007 Feb 28
PMID 17323714
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Atopic dermatitis is a common inflammatory skin condition that usually affects children. It is a chronic disease, with periods of remission and flare-ups, that adversely affects the quality of life of patients and their families. Aggressive therapy with emollients is an important intervention for patients with atopic dermatitis. Patients should avoid individual disease triggers and allergens. Topical corticosteroids are the mainstay of treatment for flare-ups and are the standard to which other treatments are compared. Topical calcineurin inhibitors should not be used in patients younger than two years or in those who are immunosuppressed, and should be secondline therapies in other patients. Rarely, systemic agents (e.g., cyclosporine, interferon gamma-1b, oral corticosteroids) may be considered in adults.

Citing Articles

Efficacy of a Multi-lamellar Emulsion Containing a Synthetic Sphingosine Kinase 1 Activator and Pseudoceramide in Patients with Atopic Dermatitis: A Randomized Controlled Trial.

Lee S, Park J, Kim D, Jeong W, Hwang C, Kim H Dermatol Ther (Heidelb). 2024; 14(9):2591-2605.

PMID: 39212849 PMC: 11393266. DOI: 10.1007/s13555-024-01254-5.


Novel Vehicles For Drug Delivery in Atopic Dermatitis: A Narrative Review.

Farkouh C, Anthony M, Abdi P, Santiago N, Farkouh M Dermatol Pract Concept. 2023; 13(4).

PMID: 37992345 PMC: 10656133. DOI: 10.5826/dpc.1304a216.


Health-Related Behaviors and Psychological Status of Adolescent Patients with Atopic Dermatitis: The 2019 Korea Youth Risk Behavior Web-Based Survey.

Park J, Prochnow T, Chang J, Kim S Patient Prefer Adherence. 2023; 17:739-747.

PMID: 36970303 PMC: 10032138. DOI: 10.2147/PPA.S406125.


The Contest of Nanoparticles: Searching for the Most Effective Topical Delivery of Corticosteroids.

Kalvodova A, Dvorakova K, Petrova E, Michniak-Kohn B, Zbytovska J Pharmaceutics. 2023; 15(2).

PMID: 36839836 PMC: 9962773. DOI: 10.3390/pharmaceutics15020513.


.

Costanzo A, Furneri G, Bitonti R, Pedone M, Fanelli F, Di Turi R Glob Reg Health Technol Assess. 2023; 7:57-65.

PMID: 36627954 PMC: 9677604. DOI: 10.33393/grhta.2020.710.